Parkinsonism & related disorders · 2026
Striatal DAT and disease progression in Parkinson's disease: New evidence from autonomic dysfunction.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Haohan, Li Rong, Jiao Yuxiang, Niu Yuxin, Hao Xiaodi, Shimada Hitoshi, Shen Yu, Ma Kai, Chen Shuai, Zhang Jiewen
Аннотация
BACKGROUND: Striatal dopamine transporter (DAT) availability is a reliable marker of dopaminergic degeneration and has been shown to predict both motor worsening and cognitive decline in Parkinson's disease (PD). Although cross-sectional studies suggest that lower DAT is associated with autonomic dysfunction, its prognostic value for longitudinal autonomic progression remains unknown.
METHODS: This study investigated the longitudinal association between striatal DAT availability and autonomic dysfunction in 1,219 individuals with PD. Single-photon emission computed tomography of DAT (DAT-SPECT) and Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT) scores were assessed at baseline and annually over a 5-year follow-up period. A linear mixed-effects model was employed to evaluate the interaction between DAT uptake (baseline or time-varying) and time.
RESULTS: The mean baseline age and disease duration of the 1,219 participants were 63.0 years and 1.2 years, respectively. SCOPA-AUT scores increased by 0.8 points per year (P < 0.001). Linear mixed-effects models demonstrated that the interaction between baseline DAT availability and time was significant in the overall striatum (β = -0.54, P = 0.012), after adjustment for age, sex, baseline disease duration, DAT asymmetry index, MDS-UPDRS-III scores, and levodopa equivalent daily dose. The interaction between time-varying striatal DAT and time produced consistent results (β = -0.63, P = 0.018).
CONCLUSION: Higher striatal DAT uptake was associated with slower progression of autonomic dysfunction, extending its established prognostic value beyond motor and cognitive decline.
METHODS: This study investigated the longitudinal association between striatal DAT availability and autonomic dysfunction in 1,219 individuals with PD. Single-photon emission computed tomography of DAT (DAT-SPECT) and Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT) scores were assessed at baseline and annually over a 5-year follow-up period. A linear mixed-effects model was employed to evaluate the interaction between DAT uptake (baseline or time-varying) and time.
RESULTS: The mean baseline age and disease duration of the 1,219 participants were 63.0 years and 1.2 years, respectively. SCOPA-AUT scores increased by 0.8 points per year (P < 0.001). Linear mixed-effects models demonstrated that the interaction between baseline DAT availability and time was significant in the overall striatum (β = -0.54, P = 0.012), after adjustment for age, sex, baseline disease duration, DAT asymmetry index, MDS-UPDRS-III scores, and levodopa equivalent daily dose. The interaction between time-varying striatal DAT and time produced consistent results (β = -0.63, P = 0.018).
CONCLUSION: Higher striatal DAT uptake was associated with slower progression of autonomic dysfunction, extending its established prognostic value beyond motor and cognitive decline.